Literature DB >> 15629600

The role of radiotherapy in the treatment of malignant salivary gland tumors.

Chris H J Terhaard1, Herman Lubsen, Coen R N Rasch, Peter C Levendag, Hans H A M Kaanders, Reineke E Tjho-Heslinga, Piet L A van Den Ende, Fred Burlage.   

Abstract

PURPOSE: We analyzed the role of primary and postoperative low linear energy transfer radiotherapy in 538 patients treated for salivary gland cancer in centers of the Dutch Head and Neck Oncology Cooperative Group, in search for prognostic factors and dose response. METHODS AND MATERIALS: The tumor was located in the parotid gland in 59%, submandibular gland in 14%, oral cavity in 23%, and elsewhere in 5%. In 386 of 498 patients surgery was combined with radiotherapy, with a median dose of 62 Gy. Median delay between surgery and radiotherapy was 6 weeks. In the postoperative radiotherapy group, adverse prognostic factors prevailed. Elective radiotherapy to the neck was given in 40%, with a median dose of 50 Gy. Primary radiotherapy (n = 40) was given for unresectable disease or M(1), with a dose range of 28-74 Gy.
RESULTS: Postoperative radiotherapy improved 10-year local control significantly compared with surgery alone in T(3-4) tumors (84% vs. 18%), in patients with close (95% vs. 55%) and incomplete resection (82% vs. 44%), in bone invasion (86% vs. 54%), and perineural invasion (88% vs. 60%). Local control was not correlated with interval between surgery and radiotherapy. No dose-response relationship was shown. Postoperative radiotherapy significantly improved regional control in the pN(+) neck (86% vs. 62% for surgery alone). A rating scale for different sites, T stage, and histologic type may be applied to calculate the risk of disease in the neck at presentation, and so indicate the need for elective neck treatment. A marginal dose-response was seen, in favor of a dose > or =46 Gy. A clear dose-response relationship was shown for patients treated with primary radiotherapy. Five-year local control was 50% with a dose of 66-70 Gy.
CONCLUSIONS: Postoperative radiotherapy with a dose of at least 60 Gy is indicated for patients with T(3-4) tumors, incomplete or close resection, bone invasion, perineural invasion, and pN(+). In unresectable tumors, a dose of at least 66 Gy is advisable.

Entities:  

Mesh:

Year:  2005        PMID: 15629600     DOI: 10.1016/j.ijrobp.2004.03.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  74 in total

Review 1.  Salivary acinic cell carcinoma: reappraisal and update.

Authors:  V Vander Poorten; A Triantafyllou; L D R Thompson; J Bishop; E Hauben; J Hunt; A Skalova; G Stenman; R P Takes; D R Gnepp; H Hellquist; B Wenig; D Bell; A Rinaldo; A Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-19       Impact factor: 2.503

2.  Pattern of recurrent disease in major salivary gland adenocystic carcinoma.

Authors:  Karoliina Hirvonen; Leif Bäck; Kauko Saarilahti; Ilmo Leivo; Jaana Hagström; Antti A Mäkitie
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

3.  [On the diagnosis and treatment of parotid gland tumors. Results of a nationwide survey of ENT hospitals in Germany].

Authors:  S F Preuss; O Guntinas-Lichius
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

4.  Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.

Authors:  Trevor M Feinstein; Stephen Y Lai; Diana Lenzner; William Gooding; Robert L Ferris; Jennifer R Grandis; Eugene N Myers; Jonas T Johnson; Dwight E Heron; Athanassios Argiris
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

5.  Results of surgery plus postoperative radiotherapy for patients with malignant parotid tumor.

Authors:  Shogo Matsuda; Hiroyoshi Iguchi; Takuhito Tada; Masako Hosono; Masahiko Osawa; Yuuko Kuwae; Hideyuki Morimoto; Eiichiro Okazaki; Kosuke Amano; Yoshitaka Miki; Shinichi Tsutsumi; Yasuhiko Shimatani; Yukio Miki
Journal:  Jpn J Radiol       Date:  2015-07-10       Impact factor: 2.374

6.  Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: Incidence and outcomes by site and histological type.

Authors:  Ashley J Hay; Jocelyn Migliacci; Daniella Karassawa Zanoni; Marlena McGill; Snehal Patel; Ian Ganly
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

7.  Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review.

Authors:  Jay K Ferrell; Jess C Mace; Daniel Clayburgh
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-01-16       Impact factor: 2.503

8.  Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.

Authors:  Limin Liu; Herui Wang; Jing Cui; Qi Zhang; Wei Zhang; Wanlin Xu; Hao Lu; Shengwen Liu; Shukun Shen; Francia Fang; Lei Li; Wenjun Yang; Zhengping Zhuang; Jiang Li
Journal:  Cell Physiol Biochem       Date:  2018-10-03

Review 9.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

10.  Treatment Results of Major Salivary Gland Cancer by Surgery with or without Postoperative Radiation Therapy.

Authors:  Jae Myoung Noh; Yong Chan Ahn; Heerim Nam; Won Park; Chung-Hwan Baek; Young-Ik Son; Han-Sin Jeong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-06-30       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.